70 related articles for article (PubMed ID: 20945125)
21. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
Alvarez-Diez TM; Zheng J
Chem Res Toxicol; 2004 Feb; 17(2):150-7. PubMed ID: 14967002
[TBL] [Abstract][Full Text] [Related]
22. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
23. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications.
Park BK; Kitteringham NR
Xenobiotica; 1990 Nov; 20(11):1171-85. PubMed ID: 2275213
[TBL] [Abstract][Full Text] [Related]
24. Six patterns of drug-drug interactions.
Armstrong SC; Cozza KL; Sandson NB
Psychosomatics; 2003; 44(3):255-8. PubMed ID: 12724509
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
26. Structural diversity of cytochrome P450 enzyme system.
Omura T
J Biochem; 2010 Mar; 147(3):297-306. PubMed ID: 20068028
[TBL] [Abstract][Full Text] [Related]
27. Patterns of interactions of reaction pairs in metabolic networks.
Bruck J; Ebenhöh O; Heinrich R
Genome Inform; 2006; 17(1):208-18. PubMed ID: 17503370
[TBL] [Abstract][Full Text] [Related]
28. [Application of theoretical and synthetic models to cytochrome P450 catalysed metabolic reactions].
Keserú GM
Acta Pharm Hung; 1998 Mar; 68(2):65-9. PubMed ID: 9592930
[TBL] [Abstract][Full Text] [Related]
29. Cytochromes P450 and drug discovery.
Lamb DC; Waterman MR; Kelly SL; Guengerich FP
Curr Opin Biotechnol; 2007 Dec; 18(6):504-12. PubMed ID: 18006294
[TBL] [Abstract][Full Text] [Related]
30. Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.
Li W; Tang Y; Liu H; Cheng J; Zhu W; Jiang H
Proteins; 2008 May; 71(2):938-49. PubMed ID: 18004755
[TBL] [Abstract][Full Text] [Related]
31. Focus on molecules: cytochrome P450 family 4, subfamily V, polypeptide 2 (CYP4V2).
Mackay DS; Halford S
Exp Eye Res; 2012 Sep; 102():111-2. PubMed ID: 21745470
[No Abstract] [Full Text] [Related]
32. Possible similar role of cytochrome P450 in primordial evolution of species and in chemical carcinogenesis.
Wickramasinghe RH; Villee CA
Perspect Biol Med; 1976; 19(4):473-5. PubMed ID: 958862
[No Abstract] [Full Text] [Related]
33. Human liver rate-limiting enzymes influence metabolic flux via branch points and inhibitors.
Zhao M; Qu H
BMC Genomics; 2009 Dec; 10 Suppl 3(Suppl 3):S31. PubMed ID: 19958496
[TBL] [Abstract][Full Text] [Related]
34. Introduction: cytochome P450.
Masters BS
FASEB J; 1996 Feb; 10(2):205. PubMed ID: 8641553
[No Abstract] [Full Text] [Related]
35. The molecular perspective: cytochrome p450.
Goodsell DS
Oncologist; 2001; 6(2):205-6. PubMed ID: 11306732
[No Abstract] [Full Text] [Related]
36. Developmental aspects of enzyme induction and inhibition.
Klinger W
Pharmacol Ther; 1987; 33(1):55-61. PubMed ID: 3306717
[No Abstract] [Full Text] [Related]
37. The remarkable P450s: a historical overview of these versatile hemeprotein catalysts.
Estabrook RW
FASEB J; 1996 Feb; 10(2):202-4. PubMed ID: 8641552
[No Abstract] [Full Text] [Related]
38. Chemical toxicity, cytochrome P-450, and computer graphics.
Parke DV
Regul Toxicol Pharmacol; 1987 Sep; 7(3):220-1. PubMed ID: 3685460
[No Abstract] [Full Text] [Related]
39. Drug peptide conjugates in human urine?
Mitchell S; Steventon G; Waring R
Xenobiotica; 2014 Jan; 44(1):89-93. PubMed ID: 23777287
[TBL] [Abstract][Full Text] [Related]
40. Validating phenotyping cocktails: more work needs to be done.
Ma JD; Nafziger AN; Bertino JS
J Clin Pharmacol; 2012 Nov; 52(11):1772-3; author reply 1774-5. PubMed ID: 23105127
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
